Portfolio Companies News
January 21, 2020Targovax announces encouraging data...
Preliminary data show a numerical advantage in Progression Free Survival in ONCOS-102 treated patients Robust immune activation in the experimental group, with a positive association between immune response and clinical outcome Combination treatment with ONCOS-102 and chemotherapy is well ... read more
January 21, 2020GenSight Biologics Reports its Cash...
Paris, France, January 21, 2020, 7.30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reporte... read more
January 20, 2020Invitation to presentation of the F...
Uppsala, Sweden – January 20, 2020 – As previously communicated Orexo will announce the Full Year Report 2019, incl. Q4, on Thursday, January 30 at 8.00 am CET. The same day at 2.00 pm CET, analysts, investors and media are invited to attend an audiocast with a web presentation where Nikol... read more
January 14, 2020Fusion Pharmaceuticals Announces In...
Hamilton, ON & Boston, MA – January 13, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing next-generation radiopharmaceuticals, today announced an investment commitment of up to US$20 million from Canada Pension Plan Investment Board (CPPIB). CPPIB ... read more
January 13, 2020Fusion Pharmaceuticals To Present A...
Hamilton, ON & Boston, MA – January 10, 2020 – Fusion Pharmaceuticals Inc., a privately-held, clinical-stage precision oncology company developing next-generation radiopharmaceuticals, today announced that Chief Executive Officer John Valliant, Ph.D., will present an overview of the Company... read more
October 31, 2019Q3 2019 General Market Overview
Since the start in 1996, HealthCap funds have invested in 114 portfolio companies.
43 of the portfolio companies have been taken public on nine different markets.
25 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.